Muireann Kelleher

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Rapid access multidisciplinary lymph node diagnostic clinic: analysis of 550 patients

Ian Chau, Muireann Kelleher, David Cunningham et al. · British Journal of Cancer · 2003 · 130 citations · Full text

Medicine, Oncology, Cancer Epidemiology +11

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation

Pascal Gellert, Corrinne V. Segal, Qiong Gao et al. · Nature Communications · 2016 · 43 citations · Full text

Medicine, Molecular Genetics, Oncology +16